Deltex points to study as proving its product

Oesophageal doppler monitoring specialist Deltex Medical Group announced the publication of a new trial showing “excellent results” from using ODM in thoracic surgery on Friday.

The AIM-traded company said the results of the randomised controlled trial of 100 patients undergoing lung surgery at the University of Freiburg in Germany had been published online by the British Journal of Anaesthesia.

Vascular fluids and vasoactive drugs were administered during surgery in accordance with Enhanced Recovery After Surgery Society recommended protocols.

Nine fewer ODM patients - six, compared with 15 - suffered postoperative pulmonary complications, the board said, and ODM patients had a two-day shorter stay in hospital - nine, compared with 11 days.

It was the first published randomised controlled trial studying ODM use during thoracic surgery, Deltex claimed.

“This is excellent news for large numbers of patients undergoing lung resection with one in five of them avoiding a dangerous, life shortening, complication,” said chief executive Ewan Phillips.

“The trial allows us to target thoracic surgery on top of those other specific types of surgery where the value of ODM has previously been demonstrated.

“In the NHS in England there are around 40,000 patients a year undergoing higher risk thoracic procedures with a risk of postoperative death within 30 days of 1% or higher and very few of these have fluids or vasoactive drugs administered with the aid of ODM.”